Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancer × Tamoxifen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 228 Carcinoma, Intraductal, Noninfiltrating 19 Breast Carcinoma In Situ 15 Neoplasm Metastasis 13 Neoplasms 11 Breast Neoplasms, Male 11 Ovarian Neoplasms 8 Inflammatory Breast Neoplasms 6 Glioblastoma 5 Endometrial Neoplasms 4 Central Nervous System Neoplasms 4 Prostatic Neoplasms 3 Obesity 3 Gliosarcoma 3 Fallopian Tube Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Breast Cancer Female 3 Brain Neoplasms 3 Urinary Bladder Neoplasms 2 Sleep Wake Disorders 2 Recurrence 2 Multiple Endocrine Neoplasia Type 1 2 Hot Flashes 2 Glioma 2 Fibroadenoma 2 ER+ Breast Cancer 2 Astrocytoma 2 Vitamin D Deficiency 1 Uveal Melanoma 1 Uterine Cervical Neoplasms 1

Interventions

Nivolumab 14 Surveys and Questionnaires 7 Ipilimumab 6 linrodostat 5 Standard of Care 5 Paclitaxel 5 Bevacizumab 5 temsirolimus 4 Sirolimus 4 Interviews as Topic 4 Gemcitabine 4 Docetaxel 4 relatlimab 3 Vorinostat 3 Pemetrexed 3 Erlotinib Hydrochloride 3 Cetuximab 3 Carboplatin 3 regorafenib 2 apatinib 2 abemaciclib 2 Trastuzumab 2 Sorafenib 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2 Magnetic Resonance Spectroscopy 2 Everolimus 2 Dasatinib 2 Cisplatin 2 Chlorogenic Acid 2 Capecitabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01393990 2020-03-24

A Study of LY2228820 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed

89 enrolled 30 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡